Gabapentin GR: Phase II data

In a 13-week, double-blind, U.S. Phase II trial in 124 menopausal women, 2 of 3 Gabapentin GR doses (1,800 and 2,400 mg) significantly reduced the frequency and severity of hot flashes vs. placebo. Th...